Illana Gozes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2296698/publications.pdf

Version: 2024-02-01

282 papers	17,719 citations	20817 60 h-index	18130 120 g-index
305 all docs	305 docs citations	305 times ranked	19975 citing authors

#	Article	IF	Citations
1	Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies. Biological Psychiatry, 2022, 92, 81-95.	1.3	32
2	STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimerâ€™s Disease: The Case of ADNP. Frontiers in Endocrinology, 2022, 13, 867442.	3.5	10
3	SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. Molecular Psychiatry, 2022, 27, 3316-3327.	7.9	29
4	From the Desk of the Editorâ€inâ€Chief: Excerpts from the Society for Neurochemistry (ESN) Future Perspectives for European Neurochemistry Highlighting the Symposium Asking â€œAutism, Epilepsy, Intellectual Disability Where Do These All Meet?â€. Journal of Molecular Neuroscience, 2022, 72, 1527-1529.	2.3	0
5	Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. Molecular Psychiatry, 2021, 26, 1619-1633.	7.9	60
6	Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Progress in Molecular Biology and Translational Science, 2021, 177, 65-90.	1.7	11
7	Putative Blood Somatic Mutations in Post-Traumatic Stress Disorder-Symptomatic Soldiers: High Impact of Cytoskeletal and Inflammatory Proteins. Journal of Alzheimer's Disease, 2021, 79, 1723-1734.	2.6	8
8	Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis. Frontiers in Pharmacology, 2021, 12, 638128.	3.5	7
9	Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. Molecular Psychiatry, 2021, 26, 6550-6561.	7.9	25
10	Editorial: Designing a Protocol Adopting an Artificial Intelligence (AI)â€“Driven Approach for Early Diagnosis of Late-Onset Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2021, 71, 1329-1337.	2.3	4
11	Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP. Journal of Molecular Neuroscience, 2021, 71, 1515-1524.	2.3	4
12	A Different Outlook at Psychiatric and Neurological Diseases: Brain Somatic Mutations Are Implicated in Schizophrenia. Biological Psychiatry, 2021, 90, 6-8.	1.3	4
13	Outdoor PM2.5 concentration and rate of change in COVID-19 infection in provincial capital cities in China. Scientific Reports, 2021, 11, 23206.	3.3	5
14	Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): Autism, schizophrenia, and Alzheimerâ€™s disease. , 2020, , 3-20.		2
15	Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population. Journal of Molecular Neuroscience, 2020, 70, 467-474.	2.3	12
16	Molecular Mechanisms of Cognitive Impairment and Intellectual Disabilityâ€”Virtual ESN Mini-Conference in Conjunction with the FENS Forum, July 11â€“15, 2020. Journal of Molecular Neuroscience, 2020, 70, 1927-1933.	2.3	1
17	Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Translational Psychiatry, 2020, 10, 228.	4.8	57
18	The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy. Journal of Molecular Neuroscience, 2020, 70, 1303-1312.	2.3	22

#	Article	IF	Citations
19	Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain. Journal of Molecular Neuroscience, 2020, 70, 1671-1683.	2.3	7
20	Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting. Cells, 2020, 9, 2320.	4.1	9
21	Age and Sex-Dependent ADNP Regulation of Muscle Gene Expression Is Correlated with Motor Behavior: Possible Feedback Mechanism with PACAP. International Journal of Molecular Sciences, 2020, 21, 6715.	4.1	15
22	The ADNP Syndrome and CP201 (NAP) Potential and Hope. Frontiers in Neurology, 2020, 11, 608444.	2.4	29
23	Immune-modulatory Properties of the Octapeptide NAP in Campylobacter jejuni Infected Mice Suffering from Acute Enterocolitis. Microorganisms, 2020, 8, 802.	3.6	14
24	Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis. Journal of Molecular Neuroscience, 2020, 70, 993-998.	2.3	7
25	Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond. Journal of Neural Transmission, 2020, 127, 251-263.	2.8	12
26	Neurotrophic Action of VIP. , 2020, , 383-408.		6
27	Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice. Neuropsychopharmacology, 2019, 44, 415-424.	5.4	15
28	ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging. GeroScience, 2019, 41, 321-340.	4.6	9
29	Does SCFD1 rs10139154 Polymorphism Decrease Alzheimerâ€™s Disease Risk?. Journal of Molecular Neuroscience, 2019, 69, 343-350.	2.3	15
30	A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP. Frontiers in Cellular Neuroscience, 2019, 13, 435.	3.7	10
31	The autism-mutated ADNP plays a key role in stress response. Translational Psychiatry, 2019, 9, 235.	4.8	27
32	Methods for single-cells. Journal of Neuroscience Methods, 2019, 328, 108413.	2.5	1
33	The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. Translational Psychiatry, 2019, 9, 2.	4.8	42
34	Cellular and animal models of skin alterations in the autism-related ADNP syndrome. Scientific Reports, 2019, 9, 736.	3.3	27
35	Cancer-associated stroke: Pathophysiology, detection and management (Review). International Journal of Oncology, 2019, 54, 779-796.	3.3	104
36	Neuropeptides: From Bench to Bedside. Current Pharmaceutical Design, 2019, 24, 3867-3867.	1.9	0

#	Article	IF	Citations
37	Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain. Neurochemical Research, 2019, 44, 1494-1507.	3.3	19
38	Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation. Journal of Molecular Neuroscience, 2019, 68, 321-330.	2.3	21
39	Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq. Journal of Neuroscience Methods, 2019, 323, 119-124.	2.5	6
40	NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLoS ONE, 2019, 14, e0213666.	2.5	39
41	Reduction of aluminum ion neurotoxicity through a small peptide application â€“ NAP treatment of Alzheimer's disease. Journal of Food and Drug Analysis, 2019, 27, 551-564.	1.9	18
42	The bloodâ€“brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 359-379.	3.3	41
43	Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP. Biological Psychiatry, 2019, 85, 287-297.	1.3	108
44	VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects. Frontiers in Cellular Neuroscience, 2019, 13, 589.	3.7	4
45	NAP Protects against Tau Hyperphosphorylation Through GSK3. Current Pharmaceutical Design, 2019, 24, 3868-3877.	1.9	14
46	The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. Peptides, 2018, 101, 1-9.	2.4	60
47	ADNP Regulates Cognition: A Multitasking Protein. Frontiers in Neuroscience, 2018, 12, 873.	2.8	11
48	ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect. Frontiers in Molecular Neuroscience, 2018, 11, 151.	2.9	14
49	Anti-inflammatory effects of the octapeptide NAP in human microbiota-associated mice suffering from subacute ileitis. European Journal of Microbiology and Immunology, 2018, 8, 34-40.	2.8	32
50	Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. Journal of Clinical Investigation, 2018, 128, 4956-4969.	8.2	71
51	Tau Diagnostics and Clinical Studies. Journal of Molecular Neuroscience, 2017, 63, 123-130.	2.3	11
52	ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. BioEssays, 2017, 39, 1700054.	2.5	41
53	Specific protein biomarker patterns for Alzheimerâ€™s disease: improved diagnostics in progress. EPMA Journal, 2017, 8, 255-259.	6.1	9
54	Sexual divergence in activityâ€dependent neuroprotective protein impacting autism, schizophrenia, and <scp>A</scp>lzheimer's disease. Journal of Neuroscience Research, 2017, 95, 652-660.	2.9	13

#	Article	IF	Citations
55	The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings. Frontiers in Endocrinology, 2017, 8, 107.	3.5	35
56	Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Science Translational Medicine, 2016, 8, 370ra181.	12.4	37
57	Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 313-316.	2.3	4
58	The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience. Journal of Molecular Neuroscience, 2016, 60, 410-411.	2.3	0
59	Microtubule-Tau Interaction as a Therapeutic Target for Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2016, 58, 145-152.	2.3	10
60	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
61	D-SAL and NAP: Two Peptides Sharing a SIP Domain. Journal of Molecular Neuroscience, 2016, 59, 220-231.	2.3	15
62	The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Biological Chemistry, 2016, 397, 177-184.	2.5	16
63	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimerâ€™s Disease Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 249-260.	2.6	50
64	PACAP, VIP, and ADNP: Autism and Schizophrenia. Current Topics in Neurotoxicity, 2016, , 781-792.	0.4	0
65	Anti-Inflammatory Properties of NAP in Acute Toxoplasma gondii-Induced Ileitis in Mice. European Journal of Microbiology and Immunology, 2015, 5, 210-220.	2.8	12
66	Activity-Dependent Neuroprotective Protein (ADNP): A Case Study for Highly Conserved Chordata-Specific Genes Shaping the Brain and Mutated in Cancer. Journal of Alzheimer's Disease, 2015, 45, 57-73.	2.6	44
67	Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimerâ€™s disease. SpringerPlus, 2015, 4, L37.	1.2	5
68	Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Scientific Reports, 2015, 5, 16300.	3.3	30
69	International Meeting Molecular Neurodegeneration: News and Views in Molecular Neuroscience in Health and Disease. Delmenhorst, Germany, July 20â€“22, 2015. Journal of Molecular Neuroscience, 2015, 57, 153-159.	2.3	1
70	ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Frontiers in Aging Neuroscience, 2015, 7, 205.	3.4	17
71	ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain. Peptides, 2015, 72, 75-79.	2.4	11
72	The Compassionate Side of Neuroscience: Tony Sermoneâ€™s Undiagnosed Genetic Journeyâ€”ADNP Mutation. Journal of Molecular Neuroscience, 2015, 56, 751-757.	2.3	37

#	Article	IF	Citations
73	ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. Journal of Molecular Neuroscience, 2015, 57, 304-313.	2.3	12
74	Novel Marker for the Onset of Frontotemporal Dementia: Early Increase in Activity-Dependent Neuroprotective Protein (ADNP) in the Face of Tau Mutation. PLoS ONE, 2014, 9, e87383.	2.5	51
75	New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy, 2014, 10, 2324-2332.	9.1	64
76	Intranasal <scp>NAP</scp> (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing Î±â€synuclein. Pharmacology Research and Perspectives, 2014, 2, e00065.	2.4	40
77	NAP Alpha-Aminoisobutyric Acid (IsoNAP). Journal of Molecular Neuroscience, 2014, 52, 1-9.	2.3	27
78	Study of NAP adsorption and assembly on the surface of HOPG. Peptides, 2014, 62, 55-58.	2.4	4
79	Novel Tubulin and Tau Neuroprotective Fragments Sharing Structural Similarities with the Drug Candidate NAP (Davuentide). Journal of Alzheimer's Disease, 2014, 40, S23-S36.	2.6	26
80	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	10.2	245
81	P4-274: ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (ADNP): MARKING ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. , 2014, 10, P884-P885.		0
82	Davunetide: Peptide Therapeutic in Neurological Disorders. Current Medicinal Chemistry, 2014, 21, 2591-2598.	2.4	39
83	NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport. Neurobiology of Disease, 2013, 56, 79-94.	4.4	98
84	Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: Focus on davunetide (NAP). Neuropeptides, 2013, 47, 489-495.	2.2	42
85	Tau Pathology: A Selected View on the Current Status. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 69-92.	0.6	0
86	Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). Frontiers in Endocrinology, 2012, 3, 134.	3.5	3
87	Novel Evolutionary-conserved Role for the Activity-dependent Neuroprotective Protein (ADNP) Family That Is Important for Erythropoiesis. Journal of Biological Chemistry, 2012, 287, 40173-40185.	3.4	43
88	Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclaseâ€activating polypeptide: IUPHAR Review 1. British Journal of Pharmacology, 2012, 166, 4-17.	5.4	385
89	D-NAP Prophylactic Treatment in the SOD Mutant Mouse Model of Amyotrophic Lateral Sclerosis: Review of Discovery and Treatment of Tauopathy. Journal of Molecular Neuroscience, 2012, 48, 597-602.	2.3	26
90	The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective Activities. PLoS ONE, 2012, 7, e51458.	2.5	74

#	Article	IF	Citations
91	Tau and Caspase 3 as Targets for Neuroprotection. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	36
92	Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatric Disease and Treatment, 2012, 8, 85.	2.2	30
93	A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences, 2011, 46, 597-606.	2.2	68
94	Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides, 2011, 32, 428-431.	2.4	23
95	Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmologica, 2011, 89, e126-e131.	1.1	20
96	Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. European Neuropsychopharmacology, 2011, 21, 355-361.	0.7	60
97	Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide). Current Pharmaceutical Design, 2011, 17, 3413-3417.	1.9	42
98	Editorial [Hot topic:VIP and PACAP: Novel Approaches to Brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]. Current Pharmaceutical Design, 2011, 17, 961-961.	1.9	8
99	Protection Against Tauopathy by the Drug Candidates NAP (Davunetide) and D-SAL: Biochemical, Cellular and Behavioral Aspects. Current Pharmaceutical Design, 2011, 17, 2603-2612.	1.9	38
100	Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiology of Disease, 2011, 44, 327-339.	4.4	51
101	NAP (Davunetide) Provides Functional and Structural Neuroprotection. Current Pharmaceutical Design, 2011, 17, 1040-1044.	1.9	51
102	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA Journal, 2010, 1, 305-316.	6.1	7
103	Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2010, 41, 114-120.	2.3	34
104	VIPâ€“PACAP 2010: My Own Perspective on Modulation of Cognitive and Emotional Behavior. Journal of Molecular Neuroscience, 2010, 42, 261-263.	2.3	5
105	3R tau expression modifies behavior in transgenic mice. Journal of Neuroscience Research, 2010, 88, 2727-2735.	2.9	8
106	The effects of vascular intrauterine growth retardation on cortical astrocytes. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 595-600.	1.5	21
107	Chapter 20. Davunetide (NAP) Pharmacology: Neuroprotection and Tau. RSC Drug Discovery Series, 2010, , 108-128.	0.3	9
108	NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouseâ€”A microtubule-deficient model of schizophrenia. Peptides, 2010, 31, 1368-1373.	2.4	54

#	Article	IF	Citations
109	Addressing Alzheimers Disease Tangles: From NAP to AL-108. Current Alzheimer Research, 2009, 6, 455-460.	1.4	91
110	NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiology of Disease, 2009, 34, 381-388.	4.4	124
111	NAP protects against cytochrome c release: Inhibition of the initiation of apoptosis. European Journal of Pharmacology, 2009, 618, 9-14.	3.5	31
112	NAP protects against cyanide-related microtubule destruction. Journal of Neural Transmission, 2009, 116, 1411-1416.	2.8	14
113	A Novel Method for Analyzing Mitochondrial Movement: Inhibition by Paclitaxel in a Pheochromocytoma Cell Model. Journal of Molecular Neuroscience, 2009, 37, 254-262.	2.3	18
114	Neuroprotective Protein and Carboxypeptidase E. Journal of Molecular Neuroscience, 2009, 39, 1-8.	2.3	17
115	Young Investigator Award: Derek B. Oien (Supervisor: Jackob Moskovitz), University of Kansas. Journal of Molecular Neuroscience, 2009, 39, 321-322.	2.3	0
116	PolyADPâ€ribosylation is required for longâ€term memory formation in mammals. Journal of Neurochemistry, 2009, 111, 72-79.	3.9	72
117	The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. Journal of Neurochemistry, 2009, 111, 1252-1263.	3.9	26
118	ADNP Differential Nucleus/Cytoplasm Localization in Neurons Suggests Multiple Roles in Neuronal Differentiation and Maintenance. Journal of Molecular Neuroscience, 2008, 35, 127-141.	2.3	75
119	VIP, From Gene to Behavior and Back: Summarizing my 25ÂYears of Research. Journal of Molecular Neuroscience, 2008, 36, 115-124.	2.3	33
120	In Memory of Our Teacher, Dr. Akira Arimura. Journal of Molecular Neuroscience, 2008, 36, 3-7.	2.3	0
121	Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science, 2008, 14, 321-328.	1.4	20
122	Silencing of the ADNPâ€family member, ADNP2, results in changes in cellular viability under oxidative stress. Journal of Neurochemistry, 2008, 105, 537-545.	3.9	33
123	NAP and D-SAL: neuroprotection against the Î² amyloid peptide (1â€“42). BMC Neuroscience, 2008, 9, S3.	1.9	53
124	A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 146-153.	2.5	214
125	The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs. Neuromethods, 2008, , 1-9.	0.3	0
126	Primary Cell Cultures and Cell Lines. Neuromethods, 2008, , 21-26.	0.3	1

#	Article	IF	Citations
127	NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell. Current Alzheimer Research, 2007, 4, 507-509.	1.4	69
128	NAP and ADNF-9 Protect Normal and Downs Syndrome Cortical Neurons from Oxidative Damage and Apoptosis. Current Pharmaceutical Design, 2007, 13, 1091-1098.	1.9	46
129	Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer. Current Pharmaceutical Design, 2007, 13, 1099-1104.	1.9	45
130	Activity-dependent Neuroprotective Protein Constitutes a Novel Element in the SWI/SNF Chromatin Remodeling Complex. Journal of Biological Chemistry, 2007, 282, 34448-34456.	3.4	135
131	Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 438-449.	2.5	199
132	Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Developmental Biology, 2007, 303, 814-824.	2.0	158
133	Novel analogs of VIP with multiple C-terminal domains. Peptides, 2007, 28, 1622-1630.	2.4	5
134	NAP protects hippocampal neurons against multiple toxins. Peptides, 2007, 28, 2004-2008.	2.4	32
135	Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2007, 16, 1183-1196.	4.1	20
136	Activity-dependent neuroprotective protein: From gene to drug candidate. , 2007, 114, 146-154.		76
137	Vasoactive Intestinal Peptide (VIP) Regulates Activity-Dependent Neuroprotective Protein (ADNP) Expression In Vivo. Journal of Molecular Neuroscience, 2007, 33, 278-283.	2.3	24
138	Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience, 2007, 31, 165-170.	2.3	146
139	Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Journal of Molecular Neuroscience, 2007, 31, 183-200.	2.3	28
140	Novel extended and branched N-terminal analogs of VIP. Regulatory Peptides, 2006, 137, 42-49.	1.9	8
141	VIP provides cellular protection through a specific splice variant of the PACAP receptor: A new neuroprotection target. Peptides, 2006, 27, 2867-2876.	2.4	32
142	Peptide neuroprotection through specific interaction with brain tubulin. Journal of Neurochemistry, 2006, 98, 973-984.	3.9	109
143	Vasoactive Intestinal Peptide Releases Interleukin-1 from Astrocytes. Annals of the New York Academy of Sciences, 2006, 805, 280-287.	3.8	6
144	A Splice Variant to PACAP Receptor That Is Involved in Spermatogenesis Is Expressed in Astrocytes. Annals of the New York Academy of Sciences, 2006, 1070, 484-490.	3.8	7

#	Article	IF	Citations
145	NAP, a Peptide Derived from the Activityâ€Dependent Neuroprotective Protein, Modulates Macrophage Function. Annals of the New York Academy of Sciences, 2006, 1070, 500-506.	3.8	36
146	Tubulin is the Target Binding Site for NAP-Related Peptides: ADNF-9, D-NAP, and D-SAL. Journal of Molecular Neuroscience, 2006, 28, 303-308.	2.3	23
147	Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Research Reviews, 2006, 52, 107-118.	9.0	44
148	Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate. Current Alzheimer Research, 2006, 3, 197-199.	1.4	28
149	NAP Enhances Neurodevelopment of Newborn Apolipoprotein E-Deficient Mice Subjected to Hypoxia. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 332-339.	2.5	41
150	VIP-and PACAP-Related Neuroprotection. , 2006, , 1379-1384.		0
151	Receptors for VIP and PACAP in Guinea Pig Cerebral Cortex: Effects on Cyclic AMP Synthesis and Characterization by ¹²⁵I-VIP Binding. Journal of Molecular Neuroscience, 2005, 25, 215-224.	2.3	6
152	Activity-Dependent Neurotrophic Factor-9 and NAP Promote Neurite Outgrowth in Rat Hippocampal and Cortical Cultures. Journal of Molecular Neuroscience, 2005, 25, 225-238.	2.3	62
153	Summer Neuropeptide Conference: The 14th Annual Meeting of the Summer Neuropeptide Conference, Miami Beach, Florida, USA, July 5â€“9, 2004. Neuropeptides, 2005, 39, 29-33.	2.2	0
154	The Peptides ADNF-9 and NAP Increase Survival and Neurite Outgrowth of Rat Retinal Ganglion Cells In Vitro. , 2005, 46, 933.		64
155	The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Journal of Alzheimer's Disease, 2005, 6, S37-S41.	2.6	71
156	Neuroendocrine Aspects of the Molecular Chaperones ADNF and ADNP. , 2005, , 251-262.		3
157	The Expression of Activity-Dependent Neuroprotective Protein (ADNP) is Regulated by Brain Damage and Treatment of Mice with the ADNP Derived Peptide, NAP, Reduces the Severity of Traumatic Head Injury. Current Alzheimer Research, 2005, 2, 149-153.	1.4	57
158	PolyADP-Ribosylation Is Involved in Neurotrophic Activity. Journal of Neuroscience, 2005, 25, 7420-7428.	3.6	93
159	The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides, 2005, 26, 1520-1527.	2.4	25
160	Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides, 2005, 26, 2579-2584.	2.4	18
161	NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP). CNS Neuroscience & Therapeutics, 2005, 11, 353-368.	4.0	127
162	Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology, 2004, 1, 193-199.	1.6	94

#	Article	IF	Citations
163	Protective Peptides That Are Orally Active and Mechanistically Nonchiral. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1190-1197.	2.5	62
164	A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication. Journal of Biological Chemistry, 2004, 279, 28531-28538.	3.4	132
165	Neuropeptides 2003. Journal of Molecular Neuroscience, 2004, 22, 1-2.	2.3	0
166	Apolipoprotein E Knockout Mice as a Model of Behavioral Dysfunction. Journal of Molecular Neuroscience, 2004, 23, 149-150.	2.3	3
167	NAP Mechanisms of Neuroprotection. Journal of Molecular Neuroscience, 2004, 24, 067-072.	2.3	52
168	Brain Injury-Dependent Expression of Activity-Dependent Neuroprotective Protein. Journal of Molecular Neuroscience, 2004, 24, 181-188.	2.3	30
169	Parkinson's and Alzheimer's Diseases: Protein Aggregations and Neuroprotection. Journal of Molecular Neuroscience, 2004, 24, 333-336.	2.3	4
170	Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 623-640.	4.7	22
171	Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regulatory Peptides, 2004, 123, 33-41.	1.9	81
172	Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neuroscience Letters, 2004, 361, 128-131.	2.1	77
173	Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neuroscience Letters, 2004, 373, 73-78.	2.1	43
174	Antagonism of VIP-Stimulated Cyclic AMP Formation in Chick Brain. Journal of Molecular Neuroscience, 2003, 20, 163-172.	2.3	10
175	From Vasoactive Intestinal Peptide (VIP) Through Activity-Dependent Neuroprotective Protein (ADNP) to NAP: A View of Neuroprotection and Cell Division. Journal of Molecular Neuroscience, 2003, 20, 315-322.	2.3	91
176	Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides, 2003, 37, 111-119.	2.2	57
177	Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Developmental Brain Research, 2003, 144, 83-90.	1.7	224
178	The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides, 2003, 24, 1413-1423.	2.4	84
179	Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. NeuroReport, 2003, 14, 481-484.	1.2	20
180	VIP and Drug Design. Current Pharmaceutical Design, 2003, 9, 483-494.	1.9	41

#	Article	IF	Citations
181	NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death. Stroke, 2002, 33, 1085-1092.	2.0	120
182	A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sciences, 2002, 71, 2543-2552.	4.3	11
183	The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. Regulatory Peptides, 2002, 108, 175-177.	1.9	8
184	In vitro and in vivo treatment of colon cancer by VIP antagonists. Regulatory Peptides, 2002, 109, 127-133.	1.9	23
185	Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. American Journal of Obstetrics and Gynecology, 2002, 187, 973-976.	1.3	19
186	Peptides as drug candidates against Alzheimer's disease. Drug Development Research, 2002, 56, 475-481.	2.9	7
187	NAP accelerates the performance of normal rats in the water maze. Journal of Molecular Neuroscience, 2002, 19, 167-170.	2.3	34
188	Neuropeptides in the New Millennium. Journal of Molecular Neuroscience, 2002, 18, 1-4.	2.3	1
189	(N-stearyl, Norleucine¹⁷)VIPhybrid is a Broad Spectrum Vasoactive Intestinal Peptide Receptor Antagonist. Journal of Molecular Neuroscience, 2002, 18, 29-36.	2.3	23
190	A Single Administration of the Peptide NAP Induces Long-Term Protective Changes Against the Consequences of Head Injury. Journal of Molecular Neuroscience, 2002, 18, 37-46.	2.3	31
191	Protein Synthesis in Nuclei. Journal of Molecular Neuroscience, 2002, 18, 167-168.	2.3	2
192	Tau as a Drug Target in Alzheimer's Disease. Journal of Molecular Neuroscience, 2002, 19, 337-338.	2.3	11
193	Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters, 2001, 307, 167-170.	2.1	36
194	Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends in Neurosciences, 2001, 24, 700-705.	8.6	79
195	A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer, 2001, 92, 2172-2180.	4.1	33
196	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Research and Treatment, 2001, 68, 55-64.	2.5	47
197	VIP and Peptides Related to Activity-Dependent Neurotrophic Factor Protect PC12 Cells Against Oxidative Stress. Journal of Molecular Neuroscience, 2001, 15, 137-146.	2.3	69
198	VIP-Related Protection Against Iodoacetate Toxicity in Pheochromocytoma (PC12) Cells: A Model for Ischemic/Hypoxic Injury. Journal of Molecular Neuroscience, 2001, 15, 147-154.	2.3	53

#	Article	IF	Citations
199	Alzheimer's Disease: My Point of View (Editor's Note). Journal of Molecular Neuroscience, 2001, 17, 269-270.	2.3	1
200	A Vasoactive Intestinal Peptide Antagonist Inhibits the Growth of Glioblastoma Cells. Journal of Molecular Neuroscience, 2001, 17, 331-340.	2.3	26
201	Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein. Journal of Biological Chemistry, 2001, 276, 708-714.	3.4	208
202	IGF-I as a Mediator of VIP/Activity-Dependent Neurotrophic Factor-Stimulated Embryonic Growth. Endocrinology, 2001, 142, 3348-3353.	2.8	28
203	Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits. , 2001, , 363-370.		1
204	CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Research, 2000, 868, 31-38.	2.2	59
205	Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease1This manuscript is based on a poster presented at the Brain Research Interactive Symposium on â€œNeuropeptides at the Millenniumâ€, Miami, October 1999.1. Brain Research, 2000, 854, 257-262.	2.2	147
206	A New Concept in the Pharmacology of Neuroprotection. Journal of Molecular Neuroscience, 2000, 14, 061-068.	2.3	83
207	Experimental intrauterine growth retardation alters renal development. Pediatric Nephrology, 2000, 15, 192-195.	1.7	109
208	Vasoactive Intestinal Peptide and Pituitary Adenylyl Cyclase-Activating Polypeptide Inhibit Tumor Necrosis Factor-Î± Production in Injured Spinal Cord and in Activated Microglia via a cAMP-Dependent Pathway. Journal of Neuroscience, 2000, 20, 3622-3630.	3.6	129
209	A Glia-Derived Signal Regulating Neuronal Differentiation. Journal of Neuroscience, 2000, 20, 8012-8020.	3.6	200
210	A Novel peptide prevents death in enriched neuronal cultures. Regulatory Peptides, 2000, 96, 39-43.	1.9	65
211	VIP and the potent analog, stearyl-Nle17 -VIP, induce proliferation of keratinocytes. FEBS Letters, 2000, 475, 78-83.	2.8	39
212	VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Letters, 2000, 475, 71-77.	2.8	17
213	Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia-mediated Neurotrophism. Annals of the New York Academy of Sciences, 1999, 897, 17-26.	3.8	27
214	Vasoactive Intestinal Peptide Regulates Embryonic Growth Through the Action of Activity-dependent Neurotrophic Factor. Annals of the New York Academy of Sciences, 1999, 897, 92-100.	3.8	15
215	A Novel Signaling Molecule for Neuropeptide Action: Activityâ€dependent Neuroprotective Protein. Annals of the New York Academy of Sciences, 1999, 897, 125-135.	3.8	60
216	Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. Anatomy and Embryology, 1999, 200, 65-71.	1.5	27

#	Article	IF	Citations
217	Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus. , 1999, 9, 534-541.		30
218	A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neuroscience Letters, 1999, 264, 9-12.	2.1	46
219	Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regulatory Peptides, 1999, 84, 55-67.	1.9	29
220	SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides, 1999, 20, 629-633.	2.4	22
221	Activityâ€Dependent Neurotrophic Factor Peptide (ADNF9) Protects Neurons Against Oxidative Stressâ€Induced Death. Journal of Neurochemistry, 1999, 73, 2341-2347.	3.9	56
222	Complete Sequence of a Novel Protein Containing a Femtomolarâ€Activityâ€Dependent Neuroprotective Peptide. Journal of Neurochemistry, 1999, 72, 1283-1293.	3.9	346
223	Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochemical Research, 1998, 23, 689-693.	3.3	12
224	In Memory of Victor Mutt: Discoveries of Biologically Important Peptides. Journal of Molecular Neuroscience, 1998, 11, 105-108.	2.3	1
225	Stress Genes in the Nervous System During Development and Aging Diseases. Annals of the New York Academy of Sciences, 1998, 851, 123-128.	3.8	9
226	VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar-Acting Neuroprotective Peptide. Annals of the New York Academy of Sciences, 1998, 865, 207-212.	3.8	38
227	Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motilitya. Annals of the New York Academy of Sciences, 1998, 865, 266-273.	3.8	9
228	The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line. Neuroscience Letters, 1998, 250, 37-40.	2.1	52
229	Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor Î± Transcriptional Activation by Regulating Nuclear Factor-ÎB and cAMP Response Element-binding Protein/c-Jun. Journal of Biological Chemistry, 1998, 273, 31427-31436.	3.4	165
230	Involvement of Pituitary Adenylate Cyclaseâ€Activating Polypeptide II Vasoactive Intestinal Peptide 2 Receptor in Mouse Neocortical Astrocytogenesis. Journal of Neurochemistry, 1998, 70, 2165-2173.	3.9	53
231	Neurobehavioral Development of Neonatal Mice Following Blockade of VIP During the Early Embryonic Period. Peptides, 1997, 18, 1131-1137.	2.4	49
232	Identity of Neurotrophic Molecules Released from Astroglia by Vasoactive Intestinal Peptide. Annals of the New York Academy of Sciences, 1997, 814, 167-173.	3.8	42
233	Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Developmental Brain Research, 1997, 99, 167-175.	1.7	50
234	Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. Journal of Molecular Neuroscience, 1997, 9, 211-222.	2.3	71

#	Article	IF	Citations
235	Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease. , 1997, 33, 329-342.		59
236	Regulation of VIP gene expression in general. Journal of Molecular Neuroscience, 1996, 7, 99-110.	2.3	20
237	Activity-dependent neurotrophic factor (ADNF). Journal of Molecular Neuroscience, 1996, 7, 235-244.	2.3	64
238	A VIP hybrid antagonist: From developmental neurobiology to clinical applications. Cellular and Molecular Neurobiology, 1995, 15, 675-687.	3.3	21
239	Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain. Annals of the New York Academy of Sciences, 1994, 739, 211-225.	3.8	30
240	Neuropeptide Regulation of Mitosis. Annals of the New York Academy of Sciences, 1994, 739, 253-261.	3.8	9
241	PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR SUBTYPES IN RAT TISSUES: INVESTIGATION OF RECEPTOR BINDING, A NOVEL VIP RECEPTOR ANTAGONIST AND CHEMICAL CROSS-LINKING . Biomedical Research, 1994, 15, 145-153.	0.9	3
242	Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature, 1993, 362, 155-158.	27.8	268
243	Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. Journal of Molecular Neuroscience, 1993, 4, 185-193.	2.3	52
244	Neuropeptides as growth and differentiation factors in general and VIP in particular. Journal of Molecular Neuroscience, 1993, 4, 1-9.	2.3	63
245	Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Research, 1992, 570, 49-53.	2.2	144
246	Cytokine Regulation of Neuronal Survival. Journal of Neurochemistry, 1992, 58, 454-460.	3.9	204
247	Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. Molecular Brain Research, 1991, 10, 235-240.	2.3	41
248	A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Research, 1991, 540, 319-321.	2.2	59
249	Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides, 1991, 12, 187-192.	2.4	76
250	The complete structure of the rat VIP gene. Molecular Brain Research, 1990, 7, 261-267.	2.3	46
251	Lactation Elevates Vasoactive Intestinal Peptide Messenger Ribonucleic Acid in Rat Suprachiasmatic Nucleus*. Endocrinology, 1989, 124, 181-186.	2.8	42
252	Vasoactive Intestinal Peptide Potentiates Sexual Behavior: Inhibition by Novel Antagonist*. Endocrinology, 1989, 125, 2945-2949.	2.8	100

#	Article	IF	Citations
253	VIP: Molecular biology and neurobiological function. Molecular Neurobiology, 1989, 3, 201-236.	4.0	234
254	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	2.3	22
255	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	2.3	32
256	VIP-mRNA is increased in hypertensive rats. Brain Research, 1989, 503, 304-307.	2.2	35
257	Hormonal regulation of somatostatin messenger RNA. Synapse, 1988, 2, 317-325.	1.2	39
258	Localization of vasopressin-, vasoactive intestinal polypeptide-, peptide histidine isoleucine-and somatostatin-mRNA in rat suprachiasmatic nucleus. Cell and Tissue Research, 1988, 252, 307-315.	2.9	110
259	Biosynthesis and Regulation of Expression. The Vasoactive Intestinal Peptide Gene. Annals of the New York Academy of Sciences, 1988, 527, 77-86.	3.8	8
260	Vasoactive Intestinal Peptide Gene Expression from Embryos to Aging Rats. Neuroendocrinology, 1988, 47, 27-31.	2.5	62
261	The survival of dentate gyrus neurons in dissociated culture. Developmental Brain Research, 1987, 36, 199-218.	1.7	29
262	Developmental expression of the VIP-gene in brain and intestine. Molecular Brain Research, 1987, 2, 137-148.	2.3	69
263	Developmental expression of the VIP-gene in brain and intestine. Brain Research, 1987, 388, 137-148.	2.2	26
264	The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21â†'6qter. Human Genetics, 1987, 75, 41-44.	3.8	23
265	Hypothalamic Vasoactive Intestinal Peptide Messenger Ribonucleic Acid Is Increased in Lactating Rats*. Endocrinology, 1986, 119, 2497-2501.	2.8	36
266	Detection of Vasoactive Intestinal Peptide-Encoding Messenger Ribonucleic Acid in the Rat Ovaries*. Endocrinology, 1986, 119, 2606-2610.	2.8	45
267	High levels of vasoactive intestinal peptide in human milk. Biochemical and Biophysical Research Communications, 1985, 133, 228-232.	2.1	49
268	Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides. Journal of Cellular Biochemistry, 1984, 26, 147-156.	2.6	24
269	Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). Peptides, 1984, 5, 161-166.	2.4	24
270	Monoclonal Antibodies Against Vasoactive Intestinal Polypeptide: Studies of Structure and Related Antigens. Journal of Neurochemistry, 1983, 41, 549-555.	3.9	19

#	Article	IF	Citations
271	A possible high molecular weight precursor to vasoactive intestinal polypeptide sequestered into pheochromocytoma chromaffin granules. Regulatory Peptides, 1983, 6, 111-119.	1.9	15
272	Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. Developmental Brain Research, 1982, 6, 93-97.	1.7	24
273	Multiple tubulin forms are expressed by a single neurone. Nature, 1981, 294, 477-480.	27.8	142
274	Protein Synthesis in Rat Brain Microvessels Decreases with Aging. Journal of Neurochemistry, 1981, 36, 1311-1315.	3.9	16
275	The characterization and phosphorylation of an actin-like protein in synaptosomal membranes. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1980, 624, 153-162.	1.7	19
276	Tubulin: An Integral Protein of Mammalian Synaptic Vesicle Membranes. Journal of Neurochemistry, 1980, 34, 26-32.	3.9	155
277	Translation in vitro of Rat Brain mRNA Coding for a Variety of Tubulin Forms. FEBS Journal, 1980, 103, 13-20.	0.2	59
278	The Î±-subunit of tubulin is preferentially associated with brain presynaptic membrane. FEBS Letters, 1979, 99, 86-90.	2.8	78
279	Tubulin microheterogeneity in neuroblastoma and glioma cell lines differs from that of the brain. Brain Research, 1979, 171, 171-175.	2.2	46
280	Tubulin microheterogeneity increases with rat brain maturation. Nature, 1978, 276, 411-413.	27.8	242
281	Identification of tubulin associated with rat brain myelin. FEBS Letters, 1978, 95, 169-172.	2.8	40
282	Higher ATM expression in lymphoblastoid cell lines from centenarian compared with younger women. Drug Development Research, 0, , .	2.9	2